Imperial College London
Alternate

Emeritus ProfessorJohnWarner

Faculty of Medicine, National Heart & Lung Institute

Emeritus in Paediatrics
 
 
 
//

Contact

 

j.o.warner

 
 
//

Location

 

246Medical SchoolSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Boyle:2016:10.1111/all.12848,
author = {Boyle, RJ and Tang, MLK and Chiang, WC and Chua, MC and Ismail, I and Nauta, A and Hourihane, J and Smith, P and Gold, M and Ziegler, J and Peake, J and Quinn, P and Rao, R and Brown, N and Rignierse, A and Garssen, J and Warner, JO and PATCH, study investigators},
doi = {10.1111/all.12848},
journal = {Allergy},
pages = {701--710},
title = {Prebiotic-supplemented partially hydrolysed cow’s milk formula for the prevention of eczema in high risk infants: a randomised controlled trial},
url = {http://dx.doi.org/10.1111/all.12848},
volume = {71},
year = {2016}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundPrevention guidelines for infants at high risk of allergic disease recommend hydrolysed formula if formula is introduced before 6 months, but evidence is mixed. Adding specific oligosaccharides may improve outcomes.ObjectiveTo evaluate whether partially hydrolysed whey formula containing oligosaccharides (0.8 g/100 ml) (pHF-OS) can prevent eczema in high risk infants [ISRCTN65195597].MethodsWe conducted a parallel-group, multi-centre, randomised double-blind controlled trial of pHF-OS versus standard cow's milk formula. Infants with a family history of allergic disease were randomised (stratified by centre/maternal allergy) to active (n=432) or control (n=431) formula until 6 months age if formula was introduced before 18 weeks. Primary outcome was cumulative incidence of eczema by 12 months in infants randomised at 0-4 weeks (375 pHF-OS, 383 control). Secondary outcomes were cumulative incidence of eczema by 12 or 18 months in all infants randomised, immune markers at 6 months, and adverse events.ResultsEczema occurred by 12 months in 84/293 (28.7%) infants allocated to pHF-OS at 0-4 weeks age, versus 93/324 (28.7%) control (OR 0.98 95%CI 0.68, 1.40; P=0.90), and 107/347 (30.8%) pHF-OS versus 112/370 (30.3%) control in all infants randomised (OR 0.99 95%CI 0.71, 1.37; P=0.94). pHF-OS did not change most immune markers including total/specific IgE, however pHF-OS reduced cow's milk-specific IgG1 (p<0.0001), and increased regulatory T cell and plasmacytoid dendritic cell percentages. There was no group difference in adverse events.ConclusionpHF-OS does not prevent eczema in the first year in high risk infants. The immunological changes found require confirmation in a separate cohort.
AU  - Boyle,RJ
AU  - Tang,MLK
AU  - Chiang,WC
AU  - Chua,MC
AU  - Ismail,I
AU  - Nauta,A
AU  - Hourihane,J
AU  - Smith,P
AU  - Gold,M
AU  - Ziegler,J
AU  - Peake,J
AU  - Quinn,P
AU  - Rao,R
AU  - Brown,N
AU  - Rignierse,A
AU  - Garssen,J
AU  - Warner,JO
AU  - PATCH,study investigators
DO  - 10.1111/all.12848
EP  - 710
PY  - 2016///
SN  - 1398-9995
SP  - 701
TI  - Prebiotic-supplemented partially hydrolysed cow’s milk formula for the prevention of eczema in high risk infants: a randomised controlled trial
T2  - Allergy
UR  - http://dx.doi.org/10.1111/all.12848
UR  - http://hdl.handle.net/10044/1/29198
VL  - 71
ER  -
Download